Clinical Trial Update: Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study evaluating thiotepa, busulfan, and fludarabine in patients with refractory or early-relapsed aggressive B-c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive B-cell Non-hodgkin Lymphoma

Drugs mentioned

• BUSULFAN (Busulfan)
• Fludarabine (Fludarabine)
• THIOTEPA (THIOTEPA)

Snippet

Sponsor: Azienda Ospedaliera San Giovanni Battista | Conditions: B-cell Lymphoma Refractory | Phase 2 | Status: UNKNOWN